文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

整合素在癌症中的作用：生物学意义和治疗机会。

Integrins in cancer: biological implications and therapeutic opportunities.

机构信息

Department of Pathology, Moores University of California at San Diego Cancer Center, La Jolla, 92093-0803, United States.

出版信息

Nat Rev Cancer. 2010 Jan;10(1):9-22. doi: 10.1038/nrc2748.

DOI:10.1038/nrc2748
PMID:20029421
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4383089/
Abstract

The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumours. The importance of integrins in several cell types that affect tumour progression has made them an appealing target for cancer therapy. Integrin antagonists, including the alphavbeta3 and alphavbeta5 inhibitor cilengitide, have shown encouraging activity in Phase II clinical trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma. These exciting clinical developments emphasize the need to identify how integrin antagonists influence the tumour and its microenvironment.

摘要

整合素家族细胞黏附受体调节着多种细胞功能，这些功能对实体瘤的发生、发展和转移至关重要。整合素在几种影响肿瘤进展的细胞类型中的重要性使它们成为癌症治疗的一个有吸引力的靶点。整合素拮抗剂，包括 alphavbeta3 和 alphavbeta5 抑制剂西仑吉肽，在 II 期临床试验中显示出令人鼓舞的活性，西仑吉肽目前正在胶质母细胞瘤患者的 III 期试验中进行测试。这些令人兴奋的临床进展强调了需要确定整合素拮抗剂如何影响肿瘤及其微环境。

相似文献

[1]
Integrins in cancer: biological implications and therapeutic opportunities.

Nat Rev Cancer. 2010-1

[2]
Small molecule integrin antagonists in cancer therapy.

Mini Rev Med Chem. 2009-10

[3]
Targeting integrins in malignant glioma.

Target Oncol. 2010-9-4

[4]
Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.

Anticancer Res. 2012-10

[5]
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

Expert Opin Investig Drugs. 2008-8

[6]
The role of integrins in glioma biology and anti-glioma therapies.

Curr Pharm Des. 2011

[7]
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.

Clin Genitourin Cancer. 2006-3

[8]
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.

Eur J Cancer. 2003-5

[9]
Cilengitide treatment for malignant glioma: current status and future direction.

Neurol Med Chir (Tokyo). 2012

[10]
Integrins: molecular targets in cancer therapy.

Curr Oncol Rep. 2006-3

引用本文的文献

[1]
Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer Ga-pentixafor-c(RGDfK) for PET-CT imaging.

Eur J Nucl Med Mol Imaging. 2025-9-9

[2]
Role and mechanism of Integrin α5β1 in bone formation and disease.

Front Cell Dev Biol. 2025-8-14

[3]
Comprehensive exome profiling identifies mutation as a driver in gastric cancer with ovarian metastasis.

Theranostics. 2025-7-24

[4]
Amino Acid Transporters in Glioblastoma: Implications for Diagnosis, Disease Monitoring, Therapeutic Targeting, and Drug Delivery.

Mol Diagn Ther. 2025-8-22

[5]
NK-Cell-Derived Extracellular Vesicles Engineered to Carry Senolytics Eliminate Chemotherapy-Induced Senescent Osteosarcoma Cells.

J Extracell Vesicles. 2025-7

[6]
The role of exosomes in bladder cancer immunotherapy.

J Natl Cancer Cent. 2025-5-2

[7]
HIF-1 promotes murine breast cancer brain metastasis by increasing production of integrin β3-containing extracellular vesicles.

J Clin Invest. 2025-7-15

[8]
Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets.

MedComm (2020). 2025-7-11

[9]
Tissue-seeking dyes for in vivo applications.

Smart Mol. 2024-10-24

[10]
Fibulin-7 and its bioactive fragments: emerging immunomodulatory roles in disease.

Inflamm Res. 2025-7-7

本文引用的文献

[1]
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

J Clin Oncol. 2010-5-3

[2]
An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression.

Nat Med. 2009-10

[3]
Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo.

Mol Ther. 2009-6

[4]
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Cancer Cell. 2009-3-3

[5]
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Cancer Cell. 2009-3-3

[6]
Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis.

Cancer Res. 2009-2-15

[7]
Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis.

Cancer Res. 2009-2-15

[8]
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.

J Clin Invest. 2009-2

[9]
Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.

Cancer Res. 2009-1-15

[10]
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.

Cancer Res. 2009-1-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索